Editorial discussing the need for new, advanced manufacturing platforms to be developed in order for advanced stem cell therapies, that is, cell and gene therapies, to achieve widespread clinical application, by Qasim A Rafiq, Karen Twomey, Michael Kulik et al. (from various organizations such as Fraunhofer Institute for Production Technology IPT in Germany and Cell & Gene Therapy Catapult in the UK).
Cell and gene therapies could treat conditions that currently have unmet need, such as many age-associated diseases, and thereby could provide not just socioeconomic as well as patient health benefit. However, expected manufacture of these advanced therapies needs to overcome technical challenges in the large-scale manufacture of consistent and effective products, as well as cost issues.
This Editorial by Qasim A Rafiq, Karen Twomey, Michael Kulik et al. from organizations such as REMEDI and Orbsen Therapeutics (Ireland) and Aston Medical Research Institute (UK) discusses the need for new, advanced manufacturing platforms to be developed in order for advanced stem cell therapies to achieve widespread clinical application, concluding in the need for a multidisciplinary approach to tackle the engineering challenge of developing scalable bioprocesses and integrate within an automated, modular facility.
Rafiq QA, Twomey K, Kulik M et al. Developing an automated robotic factory for novel stem cell therapy production. Regen. Med. 11(4), 351—354 (2016).